Citadel Advisors
COLL icon

Citadel Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Citadel Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
+10,100
New +$345K ﹤0.01% 10660
2025
Q2 		– Sell
-5,600
Closed -$167K – 12849
2025
Q1 		$167K Sell
5,600
-3,700
-40% -$113K ﹤0.01% 10703
2024
Q4 		$266K Sell
9,300
-500
-5% -$16.5K ﹤0.01% 9901
2024
Q3 		$379K Buy
9,800
+1,500
+18% +$53.5K ﹤0.01% 8826
2024
Q2 		$267K Buy
8,300
+3,200
+63% +$111K ﹤0.01% 9362
2024
Q1 		$198K Buy
5,100
+4,100
+410% +$143K ﹤0.01% 10335
2023
Q4 		$30.8K Buy
+1,000
New +$25.1K ﹤0.01% 12245
2023
Q3 		– Sell
-100
Closed -$2.15K – 14374
2023
Q2 		$2.15K Sell
100
-1,600
-94% -$36.3K ﹤0.01% 13819
2023
Q1 		$40.8K Buy
1,700
+300
+21% +$7.96K ﹤0.01% 12411
2022
Q4 		$32.5K Buy
+1,400
New +$28.2K ﹤0.01% 12637
2022
Q2 		– Sell
-13,300
Closed -$271K – 13004
2022
Q1 		$271K Buy
+13,300
New +$251K ﹤0.01% 10810
2021
Q2 		– Sell
-10,500
Closed -$249K – 13736
2021
Q1 		$249K Sell
10,500
-11,800
-53% -$280K ﹤0.01% 11241
2020
Q4 		$447K Buy
+22,300
New +$435K ﹤0.01% 8353
2018
Q4 		– Sell
-18,900
Closed -$279K – 9175
2018
Q3 		$279K Buy
18,900
+6,200
+49% +$110K ﹤0.01% 7685
2018
Q2 		$303K Sell
12,700
-7,200
-36% -$177K ﹤0.01% 7189
2018
Q1 		$508K Buy
+19,900
New +$474K ﹤0.01% 5859

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Citadel Advisors's COLL Position: Q2 2026 in Review

Citadel Advisors reduced its Collegium Pharmaceutical (COLL) stake by 43% in Q2 2026, selling an estimated $1.8M and leaving 68,592 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

Citadel Advisors first reported a position in COLL in Q1 2017 and has held it in 35 quarters since. The position peaked at $15.9M in Q4 2017. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Citadel Advisors held 68,592 shares of Collegium Pharmaceutical worth $2.48M as of Q2 2026.
  • Citadel Advisors sold 52,774 Collegium Pharmaceutical shares in Q2 2026, an estimated $1.8M.
  • Collegium Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6079 holding.
  • Citadel Advisors first reported a position in Collegium Pharmaceutical in Q1 2017 and has held it in 35 quarters since.
  • Citadel Advisors's Collegium Pharmaceutical position peaked at $15.9M in Q4 2017.
  • 280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.